If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Emgality Summary of Product Characteristics (SmPC)
Emgality® ▼ (galcanezumab): Use in Patients With Renal Impairment
Dosage adjustments are not required in patients with renal impairment.
With Renal Impairment in the Clinical Studies
with renal impairment were allowed to enroll in the phase 3 studies
(Table 1). A creatinine
clearance analysis was done at baseline to understand the level of
renal impairment in patients enrolling in phase 3 studies. However,
further subgroup analyses by renal function were not conducted
because the PK of galcanezumab was not impacted by renal function.1
1. Patients With Renal Impairment in Phase 2 and Phase 3 Galcanezumab
Renal disease risk group is from all phase 2 and phase 3
galcanezumab clinical trials.
Adjustments Are Not Required in Patients With Renal Impairment
clinical pharmacology studies to evaluate the effects of renal
impairment and hepatic impairment on the PK of galcanezumab have not
elimination of IgG monoclonal antibody is low. Similarly, IgG
monoclonal antibodies are mainly eliminated via intracellular
catabolism and hepatic impairment is not expected to influence the
clearance of galcanezumab.2
on a population PK analysis, bilirubin concentration or
Cockcroft-Gault creatinine clearance (range: 24 to 308 mL/min) did
not significantly influence the apparent clearance of galcanezumab.2
dose adjustment is required in patients with mild to moderate renal
impairment or hepatic impairment.2
is indicated for the prophylaxis of migraine in adults who have at
least 4 migraine days per month.2
recommended dose is 120 mg galcanezumab injected subcutaneously once
monthly, with a 240 mg loading dose as the initial dose.2
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= apparent clearance
= immunoglobulin G
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:February 18, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com